JANESVILLE, Wis., Jan. 6 – SHINE Technologies LLC (SHINE), a next-generation nuclear technology company, and the Department of Energy's National Nuclear Security Administration (NNSA) and Office of Environmental Management (DOE-EM) announced signing of the first-ever contracts as part of the Department's Uranium Lease and Take-back Program. The shared milestone for SHINE and the Department's efforts will help increase domestic production of molybdenum-99 (Mo-99), a crucial medical radioisotope used in over 40,000 daily medical diagnostic procedures across the United States to assist in diagnosing life-threatening diseases, including heart disease and cancer.

The NNSA's lease contract will provide SHINE with the low-enriched uranium necessary to produce Mo-99, while SHINE's contract with DOE-EM details requirements surrounding the return of any resulting radioactive waste without a commercial disposition path once Mo-99 production is complete.

"Signing these contracts with SHINE is a crucial step toward medical isotope autonomy for the United States," said Corey Hinderstein, NNSA Deputy Administrator for Defense Nuclear Nonproliferation. "Once SHINE begins production, our country will be that much closer to creating a reliable and sufficient supply of these life-saving materials right here at home, while also increasing nuclear security by reducing the use of highly enriched uranium."

The American Medical Isotopes Production Act of 2012 directed DOE/NNSA to establish a program to make uranium available to medical isotope producers in the United States. Although the Act also requires DOE to establish take-back contracts for spent nuclear fuel and radioactive waste resulting from medical isotope production without a disposal path, there is no spent fuel or radioactive waste involved in these contracts.

SHINE is steadily progressing toward Mo-99 production capability at its plant located in Janesville, Wis.

"We are incredibly proud to partner with the NNSA and DOE to be deploying an integrated irradiation and processing facility to manufacture U.S.-based, high-specific-activity (HSA) Mo-99 that millions of patients rely on every year throughout the U.S.," said SHINE CEO Greg Piefer. "We consider the ability to produce HSA Mo-99 without the need for highly enriched uranium to be a huge win for both patient access to essential medical diagnostic procedures, and for nuclear security."

Molecular Imaging Homepage